{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:15:00Z","timestamp":1784211300456,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Songjiang District Science and Technology Commission of Shanghai Municipality","award":["No.19sikigg139"],"award-info":[{"award-number":["No.19sikigg139"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05847-0","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:37:00Z","timestamp":1776346620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlation between elevated Lp(a) levels and cardiovascular risk in coronary heart disease patients with different homocysteine concentrations"],"prefix":"10.1186","volume":"26","author":[{"given":"Tao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingyan","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"11","key":"5847_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","volume":"32","author":"B Chong","year":"2025","unstructured":"Chong B, Jayabaskaran J, Jauhari SM, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050[J]. Eur J Prev Cardiol. 2025;32(11):1001\u201315.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"5847_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2022.05.033","volume":"80","author":"R Mohebi","year":"2022","unstructured":"Mohebi R, Chen C, Ibrahim NE, et al. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates[J]. J Am Coll Cardiol. 2022;80(6):565\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"5847_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-15-2517-9_1","volume":"1177","author":"C Shao","year":"2020","unstructured":"Shao C, Wang J, Tian J, et al. Coronary Artery Disease: From Mechanism to Clinical Practice[J]. Adv Exp Med Biol. 2020;1177:1\u201336.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"5847_CR4","first-page":"949","volume":"37","author":"FC Center","year":"2024","unstructured":"Center FC. D T. Report on Cardiovascular Health and Diseases in China 2023: An Updated Summary[J]. Biomed Environ Sci. 2024;37(9):949\u201392.","journal-title":"Biomed Environ Sci"},{"key":"5847_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ahj.2017.01.016","volume":"187","author":"CN Hess","year":"2017","unstructured":"Hess CN, Clare RM, Neely ML, et al. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome[J]. Am Heart J. 2017;187:194\u2013203.","journal-title":"Am Heart J"},{"issue":"Suppl 1","key":"5847_CR6","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.ihj.2023.12.010","volume":"76","author":"T Ghose","year":"2024","unstructured":"Ghose T. Lipoprotein a - Lp(a)[J]. Indian Heart J. 2024;76(Suppl 1):S117\u201320.","journal-title":"Indian Heart J"},{"key":"5847_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-14-6","volume":"14","author":"P Ganguly","year":"2015","unstructured":"Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J. 2015;14:6.","journal-title":"Nutr J"},{"issue":"1","key":"5847_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-017-02401-7","volume":"9","author":"T Li","year":"2018","unstructured":"Li T, Yu B, Liu Z, et al. Homocysteine directly interacts and activates the angiotensin II type I receptor to aggravate vascular injury[J]. Nat Commun. 2018;9(1):11.","journal-title":"Nat Commun"},{"issue":"47","key":"5847_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018019","volume":"98","author":"M Wei","year":"2019","unstructured":"Wei M, Wang L, Liu YS, et al. Homocysteine as a potential predictive factor for high major adverse cardiovascular events risk in female patients with premature acute coronary syndrome. Medicine (Baltimore). 2019;98(47):e18019.","journal-title":"Medicine (Baltimore)"},{"issue":"18","key":"5847_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025677","volume":"100","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhang J. Clinical implication of homocysteine in premature acute coronary syndrome female patients: its distribution and association with clinical characteristics and major adverse cardiovascular events risk. Medicine (Baltimore). 2021;100(18):e25677.","journal-title":"Medicine (Baltimore)"},{"issue":"41","key":"5847_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027331","volume":"100","author":"L Charach","year":"2021","unstructured":"Charach L, Blatt A, Jonas M, et al. Using the Gensini score to estimate severity of STEMI, NSTEMI, unstable angina, and anginal syndrome. Medicine (Baltimore). 2021;100(41):e27331.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"5847_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/14779072.2023.2264779","volume":"21","author":"AN Yazdani","year":"2023","unstructured":"Yazdani AN, Pletsch M, Chorbajian A, et al. Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease[J]. Expert Rev Cardiovasc Ther. 2023;21(10):675\u201392.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"5847_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-022-00317-2","volume":"74","author":"S Thupakula","year":"2022","unstructured":"Thupakula S, Nimmala S, Ravula H, et al. Emerging biomarkers for the detection of cardiovascular diseases. Egypt Heart J. 2022;74(1):77.","journal-title":"Egypt Heart J"},{"key":"5847_CR14","doi-asserted-by":"crossref","unstructured":"Song X, Sun H, Chen K. Association of Lipoprotein(a) Concentrations and Apolipoprotein(a) isoform with Coronary Artery Disease Stratification in Han Chinese. Clin Lab. 2022;68(11).","DOI":"10.7754\/Clin.Lab.2022.211232"},{"issue":"23","key":"5847_CR15","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.2174\/1381612829666230601155001","volume":"29","author":"Y Dimitroglou","year":"2023","unstructured":"Dimitroglou Y, Aggeli C, Theofilis P, et al. Lipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndromes[J]. Curr Pharm Des. 2023;29(23):1835\u201343.","journal-title":"Curr Pharm Des"},{"issue":"18","key":"5847_CR16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","volume":"81","author":"TC Gilliland","year":"2023","unstructured":"Gilliland TC, Liu Y, Mohebi R, et al. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes[J]. J Am Coll Cardiol. 2023;81(18):1780\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"5847_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12944-016-0258-8","volume":"15","author":"CA Forbes","year":"2016","unstructured":"Forbes CA, Quek RG, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review[J]. Lipids Health Dis. 2016;15:95.","journal-title":"Lipids Health Dis"},{"key":"5847_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","volume":"263","author":"R Puri","year":"2017","unstructured":"Puri R, Ballantyne CM, Hoogeveen RC, et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN[J]. Atherosclerosis. 2017;263:137\u201344.","journal-title":"Atherosclerosis"},{"issue":"7","key":"5847_CR19","doi-asserted-by":"publisher","first-page":"e13117","DOI":"10.1111\/eci.13117","volume":"49","author":"B Gencer","year":"2019","unstructured":"Gencer B, Rigamonti F, Nanchen D, et al. Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes[J]. Eur J Clin Invest. 2019;49(7):e13117.","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"5847_CR20","doi-asserted-by":"publisher","first-page":"675872873","DOI":"10.1177\/03000605211033495","volume":"49","author":"HY Wu","year":"2021","unstructured":"Wu HY, Gao TJ, Cao YW, et al. Analysis of the association and predictive value of hyperhomocysteinaemia for obstructive coronary artery disease[J]. J Int Med Res. 2021;49(7):675872873.","journal-title":"J Int Med Res"},{"issue":"2","key":"5847_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.amjcard.2008.03.022","volume":"102","author":"MG van Oijen","year":"2008","unstructured":"van Oijen MG, Claessen BE, Clappers N, et al. Prognostic value of free plasma homocysteine levels in patients hospitalized with acute coronary syndrome[J]. Am J Cardiol. 2008;102(2):135\u20139.","journal-title":"Am J Cardiol"},{"issue":"1","key":"5847_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s40001-022-00870-1","volume":"27","author":"H Wang","year":"2022","unstructured":"Wang H, Wu P, Jiang D, et al. Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a dose-response meta-analysis[J]. Eur J Med Res. 2022;27(1):261.","journal-title":"Eur J Med Res"},{"issue":"1","key":"5847_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12872-019-1157-5","volume":"19","author":"F Vadini","year":"2019","unstructured":"Vadini F, Santilli F, Casalini G, et al. Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study[J]. BMC Cardiovasc Disord. 2019;19(1):177.","journal-title":"BMC Cardiovasc Disord"},{"issue":"9","key":"5847_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S1474-4422(07)70219-3","volume":"6","author":"JD Spence","year":"2007","unstructured":"Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6(9):830\u20138.","journal-title":"Lancet Neurol"},{"issue":"3","key":"5847_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/STROKEAHA.115.011545","volume":"47","author":"LC Rutten-Jacobs","year":"2016","unstructured":"Rutten-Jacobs LC, Traylor M, Adib-Samii P, et al. Association of MTHFR C677T Genotype With Ischemic Stroke Is Confined to Cerebral Small Vessel Disease Subtype[J]. Stroke. 2016;47(3):646\u201351.","journal-title":"Stroke"},{"issue":"1","key":"5847_CR26","doi-asserted-by":"publisher","first-page":"e26707","DOI":"10.1161\/JAHA.122.026707","volume":"12","author":"Z Feng","year":"2023","unstructured":"Feng Z, Xu J, Jin A, et al. Elevated Homocysteine Intensify the Effect of Lipoprotein(a) on Stroke Recurrence[J]. J Am Heart Assoc. 2023;12(1):e26707.","journal-title":"J Am Heart Assoc"},{"key":"5847_CR27","first-page":"101120","volume":"43","author":"A Kato","year":"2022","unstructured":"Kato A, Kinoshita D, Nagata T, et al. Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndrome[J]. Int J Cardiol Heart Vasc. 2022;43:101120.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"44","key":"5847_CR28","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","volume":"41","author":"M Szarek","year":"2020","unstructured":"Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41(44):4245\u201355.","journal-title":"Eur Heart J"},{"key":"5847_CR29","doi-asserted-by":"publisher","first-page":"1362893","DOI":"10.3389\/fcvm.2024.1362893","volume":"11","author":"G Wang","year":"2024","unstructured":"Wang G, Xia M, Liang C, et al. Prognostic value of elevated lipoprotein (a) in patients with acute coronary syndromes: a systematic review and meta-analysis[J]. Front Cardiovasc Med. 2024;11:1362893.","journal-title":"Front Cardiovasc Med"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05847-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05847-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:54:01Z","timestamp":1780440841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05847-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5847"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05847-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee (full name: Medical Ethics Committee of Songjiang Hospital Affiliated to Shanghai Jiao Tong University) (approval number: 2025SQ114). The study was conducted at Songjiang Hospital Affiliated to Shanghai Jiao Tong University.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from each participant at each examination phase.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}